Appalachian Research Associates


Dr. Saxena has been involved in various aspects of clinical research since residency and fellowship, when he worked with Dr. harold Harvey at Penn State University, and with Dr. Rafael Sequiera at the University of Miami. In clinical practice, he began participating in multicentered research trials with several cardiac rhythm device companies where the research focused on evaluation of safety and efficacy of implantable leads and defibrillators. In 2015, we began enrolling our patients into phase 3 clinical trials studying disease states such as hyperlipidemia, diabetic kidney disease, peripheral arterial disease, advanced heart failure, restless leg syndrome, hypertension, and acute coronary syndromes.



Clinical research is a heavily regulated industry where pharmaceutical companies navigate the complex steps from drug conception to FDA approval for use in our patients. We feel that participation in clinical research trials has several benefits to our patients. First, it allows access to medications that show promise for difficult to treat conditions years before the general population has access to the same medications. Second, it gives closer contact between our practice and the patients we care for. it is a proven concept that more frequent interaction between patients and their doctors results in better disease control, compliance with diet and medication instruction, and better outcomes for the patients. This translates into fewer heart attacks and strokes, fewer hospitalizations, and fewer deaths from cardiovascular disease.  



At Appalachian Research Associates,  we are passionate about providing a safe and nurturing environment for our patients who entrust us to include them in the research protocols that we participate in. All these protocols are governed by central review boards that govern patient safety, monitoring outcomes and event rates as the trial proceeds. We will not bring a research protocol into our practice that we do not believe in ourselves.


The nature of placebo-controlled double blinded research protocols is that both the patient and the research team are blinded regarding which patients are receiving the study drug and which patients are receiving placebo. If you are in one of our double blinded protocols, we may ask you to inform your primary doctor to not share particular lab results with you that may inadvertently "unblind" you regarding your role in a trial. Simply knowing whether you are on placebo or active study drug can have an unavoidable "placebo effect" that undermines the integrity of the research protocol. Patients never have to pay to participate in our research trials. To the contrary, we usually provide a stipend to the patients who are participating in our trials to help offset travel costs to come to their appointments. Please see the list of trials we currently participate in, to see if you qualify for one of them. 




We are adding new studies every few weeks. Please check back again, if you do not see a study you are interested in.  If you are interested in learning more about one of these studies, call one of our research coordinators at (256) 997-9200 x413 or x415





expertise. highest quality care. latest technology. convenience.